Anhui Huangshan Capsule Co Ltd

Anhui Huangshan Capsule Co Ltd maintains a strong liquidity position with a current ratio of 3.05, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity is further supported by a debt-to-equity ratio of 0, suggesting no long-term debt obligations to burden its capital structure. Free cash flow of 79.18 million CNY and operating cash flow of 84.89 million CNY in the latest period demonstrate robust cash generation. Profitability metrics show a return on equity of 6.77% and a return on assets of 5.87%, which are below the industry median for pharmaceutical companies. This suggests the company is underperforming in terms of capital efficiency and asset utilization compared to its peers. Gross profit of 134.85 million CNY on revenue of 460.42 million CNY indicates a gross margin of 29.3%, which is typical for the industry but leaves room for improvement in cost control. The company's revenue is primarily concentrated in the domestic and overseas markets, with no disclosed segment breakdown. This lack of segment reporting limits visibility into geographic performance and risk exposure. The absence of detailed geographic revenue data makes it difficult to assess the company's vulnerability to regional economic shifts or regulatory changes. Looking ahead, the company's revenue growth trajectory is uncertain. The latest financial data does not provide forward-looking guidance, and historical revenue trends are not available for analysis. However, the company's strong cash flow generation and low debt position suggest it has the financial flexibility to invest in growth opportunities or weather short-term volatility. Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt, despite the company's strong operating cash flow. The low dilution risk is supported by no near-term pressure for equity issuance, and the company has not disclosed any recent dilutive events. The absence of long-term debt and the low dilution potential reduce financial risk, but the company's reliance on cash flow for operations exposes it to liquidity constraints in a downturn. Recent events include the latest financial filing, which provides a snapshot of the company's financial health but does not include significant new developments or strategic announcements. The company's business model remains focused on capsule production, with no disclosed R&D or expansion initiatives in the latest data.